All In Biotech

Drug Trial Radar · NCT07534371

Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study

Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Mar 6, 2026

Primary completion

Jul 2026

Study completion Jul 2026

Sponsor

Lead sponsor
West China HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
First Affiliated Hospital Xi'an Jiaotong University; National Cancer Center, China; The First Affiliated Hospital of Zhengzhou University; Beijing 302 Hospital; China-Japan Friendship Hospital
First posted
Apr 16, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter retrospective cohort study designed to compare the efficacy differences between two treatment sequence-"first-line surufatinib and second-line somatostatin analogs (SSA)" versus "first-line SSA and second-line surufatinib"-in patients with advanced neuroendocrine tumors (NETs). The primary endpoint is progression-free survival (PFS) from the initiation of first-line therapy to progression on second-line treatment. Secondary endpoints include PFS for each individual line of therapy, safety profiles, and exploration of influencing factors. This study aims to identify the optimal treatment sequence and to provide real-world evidence for optimizing individualized treatment strategies for patients with advanced NETs, thereby informing clinical decision-making in routine practice.

Conditions

  • Neuroendocrine Tumors

Interventions

  • surufatinibDrug

    Oral tyrosine kinase inhibitor, 250mg or 300mg daily until disease progression or unacceptable toxicity.

  • Somatostatin AnalogsDrug

    Long-acting release formulation of octreotide or lanreotide, administered via intramuscular or deep subcutaneous injection every 4 weeks until disease progression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: From start of first-line treatment (either surufatinib or SSA) to disease progression on second-line treatment, assessed up to 60 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.